You searched for "presentation"
Focal therapy for prostate cancer – ready for prime time?
The current therapeutic ratio for radical therapy in many men with localised prostate cancer is not ideal. For a significant side-effect profile, there seems to be a small survival benefit over a 10-15 year period. A strategy that might balance...Urology Podcasts and NotebookLM
Podcasts, downloadable or streamable digital audio / video shows, have surged in popularity over the last five years due to the ubiquity of smartphones, high-speed mobile networks, and accessible content creation technology. They offer on-the-go access to expert discussions, clinical...In conversation with Ian Pearce
We were delighted to catch up with our old friend, Ian Pearce, former Editor of Urology News and new President of BAUS. Can you tell us a little bit about what led you into the field of urology and the...Mo Belal: a journey of perseverance, resilience and representation
In this interview, we have the privilege of speaking with Mr Mo Belal, a leading consultant urologist whose career and life took an extraordinary turn following a spinal injury. Renowned for his expertise and dedication to patient care, Mr Belal...
The future of bladder-sparing therapy is bright
Trimodal therapy (TMT), combining optimal transurethral resection of bladder tumour (TURBT) and concurrent chemoradiotherapy, has garnered significant attention for managing muscle-invasive bladder cancer (MIBC). This approach offers the potential for bladder preservation while delivering oncological outcomes comparable to radical cystectomy....International urology returns to Scotland
Founded in 1907, the SIU has established itself as the premier international professional society for urologists. As global interdependence increases, so does the relevance of the Society’s mission to enable urologists in all nations to apply the highest standards of...Bladder carcinoma MRI
Bladder malignancy is one of the commonest malignancies of the renal tract, accounting for approximately 6% of male malignancy and 2% of female malignancy. The incidence increases with patient age with 70% of patients being over the age of 65...IBSA UK&I launches Perovial®: the first licensed injectable option for men with acute Peyronie’s disease
A clinically supported option for early intervention in a historically underdiagnosed and undertreated condition. IBSA UK&I today (Monday 2 February 2026) announces the launch of Perovial®, the first licensed hyaluronic acid injectable indicated for the management of Peyronie’s disease (PD)...Demanding cases or nightmares in endourology? May/June 2017
In the sixth article in this series the authors describe endourology nightmares involving ileal conduits and calculi. Case 1 A 69-year-old man who had a cystectomy and ileal conduit for muscle invasive bladder cancer, presented with an acute kidney injury...Botulinum toxin – from the sausage poison to urology
Botulinum toxin is the first biological toxin to be licensed for use in treating human disease and since its first therapeutic use in the early 1980s for strabismus has become widely used in the fields of ophthalmology, cosmetic surgery, migraine...Keeping your eye on the ball: atypical presentations of testicular malignancy
Most testicular cancers present with a painless lump on the testes, and most are confidently diagnosed on examination and ultrasound. They have an excellent prognosis, with 90% patients alive at 10 years [1]. However, advanced testicular cancer, or those with...
